

**OVERT AND SUBCLINICAL
REACTIONS TO STREPTOKINASE IN
ACUTE MYOCARDIAL INFARCTION
AND IMPLICATION ON THE RENAL
FUNCTION**

Thesis submitted for partial fulfillment of the
Master Degree of Cardiology

Presented By
Lydia Ragy Iskander
M.B.B.Ch.



Supervised By
Prof. Dr. Ramez Gundy
Professor of Cardiology
Faculty of Medicine
Ain Shams University

52611

Dr. Mohsen Mahdy
Lecturer of Cardiology
Ain Shams University

Dr. Hanaa Ahmed Amer
Lecturer of Clinical Pathology
Ain Shams University

Faculty of Medicine
Ain Shams University
1996



ACKNOWLEDGMENT

First of all , thanks to God who gives us the gift of knowledge and understanding .

I would like to express my sincerest gratitude and appreciation to Prof . Dr . Ramez Gundy ,Professor of Cardiology , Ain Shams University , for his keen supervision , valuable remarks , unlimited support and guidance throughout the preparation of this work .

I also wish to thank Dr. Mohsen Mahdy , Lecturer of Cardiology and Dr . Hanaa Amer , Lecturer of Clinical Pathology ,for their constant help , encouragement and unfailing advice , and who have contributed a lot to the delivery of this work .

TABLE OF CONTENTS

1. Introduction	3
Review of Literature	
2. Thrombolysis in Acute Myocardial Infarction	6
3. Thrombolytic Agents	12
- Urokinase [UK]	17
- Tissue Plasminogen Activator [t-PA]	19
- Single Chain Urokinase Plasminogen Activator [scu- PA]	22
- Anisoylated Plasminogen Streptokinase Activator Complex [APSAC]	25
- Streptokinase [SK]	27
4. Streptokinase Reactions	30
5. Streptokinase Antibodies	38
6. Streptokinase and Renal Functions	43
Materials and Methods	
7. Study	47
8. Results	55
9. Discussion	74
Conclusion	85
Summary	86
10. References	89
Arabic Summary	

LIST OF TABLES AND FIGURES

Table 1	16
Table 2	56
Table 3	60
Table 4	61
Table 5	66
Table 6	68
Figure 1	62
Figure 2	63
Figure 3	69
Figure 4	70
Figure 5	71
Figure 6	72

INTRODUCTION



INTRODUCTION

Acute myocardial infarction describes the development of ischemia and necrosis of a portion of the myocardium . It is a common manifestation of ischemic heart disease and a leading cause of serious cardiac complications (**Goldberger and Wheat, 1983**) .

Almost all myocardial infarctions result from atherosclerosis of the coronary arteries ,generally with superimposed coronary thrombosis . The genesis of the coronary atherosclerotic lesion is a complex and controversial issue , and a number of risk factors have been associated with the development of atherosclerosis .However , regardless of the etiology and pathogenesis of the atherosclerotic process , the end result is plaques that cause luminal narrowing of the coronary arterial tree and in many instances ,a thrombus that causes further narrowing and often total occlusion (**Baroldi , 1979**) .

Below a certain critical level of blood flow , myocardial cells develop ischemic injury .The pathophysiological studies revealed that irreversible myocardial damage occurs four to six hours following coronary occlusion , and trials of reperfusion should be performed within that period (**Kloner , 1983**) .

In 1980, before the introduction of thrombolytic therapy , the mortality rates during hospitalization and the year following infarction were approximately ten percent (**Braunwald ,1987**) . But now thrombolytic therapy has been effective in reducing the morbidity



and mortality of acute myocardial infarction (**Yusuf et al. , 1985**) .

Three thrombolytic agents ,Streptokinase [SK] , recombinant tissue type plasminogen activator , [rtPA] , and anisolyated plasminogen streptokinase activator complex [APSAC] are currently approved by the food and drug administration for intravenous use in patients with acute myocardial infarction (**Heymann and Culling , 1994**) .

By far , the greatest international experience has been accumulated with streptokinase in part owing to its low cost and demonstrated efficacy in reducing mortality rates in very large trials (**Yusuf et al. , 1985**) . It dissolves clots by conversion of plasminogen to plasmin which is a fibrinolytic enzyme (**Goldberger , 1983**) .

Recent exposure to streptococci or streptokinase ,which is a foreign protein produced by B hemolytic streptococci , produces some degree of antibody -mediated resistance to streptokinase (**James, 1973**) . In the international tPA/SK mortality trial , allergic reactions were seen in 1.7% of patients given streptokinase . The reported reactions were generally mild as rigors , rashes , less often bronchospasm and dyspnea. A number of severe reactions has been documented mainly serum sickness and less often acute anaphylaxis . Also proteinuria has been documented as well (**Alexopoulos et al. , 1990**) . Hypotension is expected in four to ten % . Bleeding complications are of course the most important and most serious . Seventy



percent of bleeding of bleeding episodes occur at the site of vascular punctures (**Gore et al . , 1991**) .

Where as all these reactions are obvious clinically , less evident reactions may be over looked in routine clinical practice (**Argent and Adams , 1991**)

The aim of this study is to assess the possibility of predicting allergic reactions to streptokinase by measuring antistreptokinase antibodies before and after streptokinase therapy and by intradermal skin testing , and to determine if streptokinase infusion is associated with subclinical changes in the renal functions .

